Literature DB >> 8855555

Characterisation and purification of pyruvate:ferredoxin oxidoreductase from Giardia duodenalis.

S M Townson1, J A Upcroft, P Upcroft.   

Abstract

The major 2-oxoacid oxidoreductase (2-OR), pyruvate:ferredoxin oxidoreductase (PFOR) from Giardia duodenalis has been purified to apparent homogeneity. A second 2-OR with a preference for alpha-ketobutyrate as substrate was identified and was removed from PFOR containing fractions during purification. Only PFOR and the second 2-OR were identified in gels of crude Giardia extracts assayed for 2-OR activity. The native form of PFOR which is membrane associated, is a homodimer of 138 kDa subunits. Pyruvate is the preferred substrate: alpha-ketobutyrate and oxaloacetate, but not phenyl-pyruvate or alpha-ketoglutarate, are decarboxylated. PFOR from Giardia is more stable than PFOR from most other organisms and purified PFOR can be stored without deterioration at -70 degrees C. Purified PFOR donates electrons to Giardia ferredoxin (Fd I) with concomitant reduction of metronidazole. However, two other Giardia ferredoxins did not accept electrons from PFOR. Consistent with the involvement of PFOR in metronidazole activation, the activity of pyruvate dependent 2-OR activity was decreased in all metronidazole-resistant lines tested but not in furazolidone-resistant lines. The presence of three different ferredoxins and two 2-ORs in Giardia suggests that a number of different electron transport pathways operate in this organism providing unusual metabolic flexibility for a eukaryote.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8855555     DOI: 10.1016/0166-6851(96)02661-8

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  43 in total

Review 1.  Why metronidazole is active against both bacteria and parasites.

Authors:  J Samuelson
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 2.  Origin and evolution of the mitochondrial proteome.

Authors:  C G Kurland; S G Andersson
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

3.  A new-generation 5-nitroimidazole can induce highly metronidazole-resistant Giardia lamblia in vitro.

Authors:  Linda A Dunn; Anita G Burgess; Kenia G Krauer; Lars Eckmann; Patrice Vanelle; Maxime D Crozet; Frances D Gillin; Peter Upcroft; Jacqueline A Upcroft
Journal:  Int J Antimicrob Agents       Date:  2010-04-24       Impact factor: 5.283

4.  Drug susceptibility testing of anaerobic protozoa.

Authors:  J A Upcroft; P Upcroft
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

Review 5.  Biology of Giardia lamblia.

Authors:  R D Adam
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

Review 6.  Biochemistry and evolution of anaerobic energy metabolism in eukaryotes.

Authors:  Miklós Müller; Marek Mentel; Jaap J van Hellemond; Katrin Henze; Christian Woehle; Sven B Gould; Re-Young Yu; Mark van der Giezen; Aloysius G M Tielens; William F Martin
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

Review 7.  Lipoic acid metabolism in microbial pathogens.

Authors:  Maroya D Spalding; Sean T Prigge
Journal:  Microbiol Mol Biol Rev       Date:  2010-06       Impact factor: 11.056

8.  Sawyeria marylandensis (Heterolobosea) has a hydrogenosome with novel metabolic properties.

Authors:  Maria José Barberà; Iñaki Ruiz-Trillo; Julia Y A Tufts; Amandine Bery; Jeffrey D Silberman; Andrew J Roger
Journal:  Eukaryot Cell       Date:  2010-10-29

Review 9.  Multiple secondary origins of the anaerobic lifestyle in eukaryotes.

Authors:  T Martin Embley
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-06-29       Impact factor: 6.237

Review 10.  Current therapeutics, their problems, and sulfur-containing-amino-acid metabolism as a novel target against infections by "amitochondriate" protozoan parasites.

Authors:  Vahab Ali; Tomoyoshi Nozaki
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.